UGN-302
Undisclosed oncology target
PreclinicalResearch
Key Facts
About UroGen Pharma
UroGen Pharma is a biopharmaceutical company pioneering novel treatments for uro-oncology, leveraging its proprietary RTGel™ technology platform to enable non-surgical, organ-sparing therapies. The company achieved a significant milestone with the FDA approval and commercialization of JELMYTO® for LG-UTUC, establishing a new standard of care. UroGen is advancing a pipeline of additional candidates, including UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), and is publicly traded on the NASDAQ. Its mission is to transform patient care by providing alternatives to invasive surgeries.
View full company profileTherapeutic Areas
Other Undisclosed oncology target Drugs
| Drug | Company | Phase |
|---|---|---|
| Internal Program 1 | AbCellera | Lead Optimization |
| NEX-22 | Nanexa AB | Preclinical |
| BPI-002 | BeyondSpring | Preclinical |